ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | 0.19 | -0.09 | 0.24 |
| FCF Yield | -2.99% | -3.45% | -3.39% | -4.89% |
| EV / EBITDA | -41.52 | -46.06 | -47.08 | -122.96 |
| Quality | ||||
| ROIC | -11.86% | -19.92% | -23.91% | -20.62% |
| Gross Margin | 99.45% | 99.49% | 99.65% | 100.00% |
| Cash Conversion Ratio | 1.02 | 0.86 | 0.66 | 1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 429.53% | 357.26% | 276.29% | 294.59% |
| Free Cash Flow Growth | 13.83% | 7.12% | 0.26% | 14.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.34 | -6.68 | -7.23 | -20.67 |
| Interest Coverage | 3.65 | -2.47 | -2.23 | -1.85 |
| Efficiency | ||||
| Inventory Turnover | 0.03 | 0.02 | 0.01 | 0.00 |
| Cash Conversion Cycle | 562.76 | -439.46 | -7,751.97 | 31.62 |